Researchers have discovered a new mechanism that is used by a male sex hormone essential for muscle and bone function. The ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Glenmark Pharmaceuticals receives UK approval for Winlevi, a groundbreaking topical acne treatment with unique mechanism of ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients ...

RedHill Biopharma has begun a trial to assess the combination of opaganib and darolutamide for metastatic castrate-resistant ...

Evan Y. Yu, MD, discusses the safety data from the phase 3 PEACE-3 study of enzalutamide (ENZA) combined with radium-223 ...

Dublin, Ireland and Mumbai, India and London, United Kingdom--( - February 10, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) and Glenmark Pharmaceuticals Limited (Glenmark), a ...

RedHill Biopharma (RDHL) announced the initiation of a Phase 2 clinical study to evaluate the efficacy of its opaganib candidate in combination ...